Celcuity (CELC) Lifted to “Buy” at ValuEngine
ValuEngine upgraded shares of Celcuity (NASDAQ:CELC) from a hold rating to a buy rating in a research report released on Friday.
Several other equities analysts have also issued reports on CELC. HC Wainwright initiated coverage on Celcuity in a research report on Tuesday, November 20th. They issued a buy rating and a $36.00 price objective for the company. Zacks Investment Research upgraded Celcuity from a hold rating to a buy rating and set a $26.00 price objective for the company in a research report on Thursday, February 28th.
Shares of CELC opened at $20.07 on Friday. Celcuity has a 52-week low of $13.16 and a 52-week high of $31.00. The company has a market capitalization of $209.18 million, a P/E ratio of -27.12 and a beta of 0.24.
Celcuity Company Profile
Celcuity Inc, a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the response rates of cancer patients treated with targeted therapies in the United States. The company is developing CELx tests to diagnose two new sub-types of HER2-negative breast cancer.
Recommended Story: Dividend Achievers
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.